SG10201805657PA - Composite formulation for oral administration comprising ezetimibe and rosuvastatin - Google Patents

Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Info

Publication number: SG10201805657PA
Authority: SG; Singapore
Prior art keywords: ezetimibe; rosuvastatin; composite formulation; oral administration; particle size
Prior art date: 2013-12-30

Application number

SG10201805657PA

Other languages

English (en)

Inventor

Jung Hyun Cho

Jin Cheul Kim

Yong Il Kim

Seung Jun Lee

Jae Hyun Park

Jong Soo Woo

Original Assignee

Hanmi Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-30

Filing date

2014-12-30

Publication date

2018-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53791740&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201805657P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-30 Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd

2018-08-30 Publication of SG10201805657PA publication Critical patent/SG10201805657PA/en

Links

239000002131 composite material Substances 0.000 title abstract 4
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 4
229960000815 ezetimibe Drugs 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 3
229960000672 rosuvastatin Drugs 0.000 title abstract 3
239000002245 particle Substances 0.000 abstract 2
239000007787 solid Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 1
239000000479 mixture part Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG10201805657PA 2013-12-30 2014-12-30 Composite formulation for oral administration comprising ezetimibe and rosuvastatin SG10201805657PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20130167156		2013-12-30
KR1020140071081A KR20150079373A (ko)	2013-12-30	2014-06-11	에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제

Publications (1)

Publication Number	Publication Date
SG10201805657PA true SG10201805657PA (en)	2018-08-30

Family

ID=53791740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201805657PA SG10201805657PA (en)	2013-12-30	2014-12-30	Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Country Status (25)

Country	Link
US (1)	US10434067B2 (es)
EP (1)	EP3089739A4 (es)
JP (1)	JP2017500303A (es)
KR (2)	KR20150079373A (es)
CN (1)	CN105873571B (es)
AR (1)	AR098996A1 (es)
AU (1)	AU2014374552B2 (es)
CA (1)	CA2933178A1 (es)
CL (1)	CL2016001654A1 (es)
CR (1)	CR20160293A (es)
DO (1)	DOP2016000159A (es)
GT (1)	GT201600137A (es)
MX (1)	MX2016008725A (es)
MY (1)	MY187637A (es)
NI (1)	NI201600093A (es)
PE (1)	PE20161072A1 (es)
PH (1)	PH12016501196B1 (es)
RU (1)	RU2683937C2 (es)
SG (1)	SG10201805657PA (es)
SV (1)	SV2016005236A (es)
TW (1)	TWI655944B (es)
UA (1)	UA117685C2 (es)
UY (1)	UY35932A (es)
WO (1)	WO2015102400A1 (es)
ZA (1)	ZA201603934B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3003149C (en) *	2015-10-30	2023-10-31	Cancer Prevention Pharmaceuticals, Inc.	Eflornithine and sulindac, fixed dose combination formulation
EP3243506A1 (en)	2016-05-09	2017-11-15	Adamed sp. z o.o.	Pharmaceutical composition
JP2017210455A (ja) *	2016-05-27	2017-11-30	ニプロ株式会社	エゼチミブ含有医薬組成物
CZ2016539A3 (cs)	2016-09-05	2018-03-14	Zentiva, K.S.	Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs)	2016-09-05	2018-03-14	Zentiva, K.S.	Farmaceutická kompozice obsahující dvě rozdílné účinné látky
KR101910902B1 (ko) *	2016-11-03	2018-10-24	한미약품 주식회사	암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102206535B1 (ko) *	2016-11-29	2021-01-22	한미약품 주식회사	에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
JP6848469B2 (ja) *	2017-01-20	2021-03-24	ニプロ株式会社	エゼチミブ含有医薬組成物の製造方法
JP7115825B2 (ja) *	2017-06-28	2022-08-09	日医工株式会社	エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) *	2017-07-11	2019-01-31	大原薬品工業株式会社	エゼチミブ含有口腔内崩壊錠及びその製造方法
JP6937195B2 (ja) *	2017-09-01	2021-09-22	興和株式会社	医薬組成物
KR102569271B1 (ko) *	2018-03-19	2023-08-23	한미약품 주식회사	에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
GR1009727B (el) *	2018-11-28	2020-04-14	Elpen Αε Φαρμακευτικη Βιομηχανια	Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
WO2021019499A1 (en)	2019-07-31	2021-02-04	TECNIMEDE - Sociedade Técnico-medicinal, SA	Solid oral multiple-unit immediate release compositions, methods and uses thereof
TW202224681A (zh) *	2020-08-25	2022-07-01	南韓商大熊製藥股份有限公司	用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
CN112999178A (zh) *	2021-03-01	2021-06-22	乐普制药科技有限公司	一种依折麦布匹伐他汀钙复方双层片剂
GB2622822A (en) *	2022-09-28	2024-04-03	Novumgen Ltd	A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
PT634175E (pt)	1993-07-15	2001-06-29	Hoffmann La Roche	Combinacao farmaceutica que contem um inibidor do sistema renina-angiotensina e o antagonista de endotelina
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AR035611A1 (es)	2000-12-20	2004-06-16	Schering Corp	2 -azetidinonas sustituidas con azucares, composicion farmaceutica, un kit, uso de dichos compuestos para la fabricacion de medicamentos utiles como agentes hipocolesterolemicos.
SI1353696T1 (sl)	2001-01-26	2007-04-30	Schering Corp	Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
KR20040032937A (ko)	2001-08-22	2004-04-17	아벤티스 파마 도이칠란트 게엠베하	1, 4-벤조티에핀-1, 1-디옥시드 유도체 및 기타 활성물질을 함유하는 배합 제제 및 이의 용도
WO2005011586A2 (en)	2003-07-28	2005-02-10	Dr. Reddy's Laboratories, Inc.	Treatment and preventi0n of cardiovascular events
EP1865947A1 (en)	2005-04-04	2007-12-19	Pontificia Universidad Catolica de Chile	The use of ezetimibe in the prevention and treatment of cholesterol gallstones
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
EA017349B1 (ru) *	2007-01-24	2012-11-30	Крка	Способ получения эзетимиба и его производных
EP2120882A2 (en) *	2007-02-23	2009-11-25	Krka	Pharmaceutical composition containing a cholesterol absorption inhibitor
US20100204195A1 (en)	2007-07-27	2010-08-12	Cipla Limited	Pharmaceutical Compositions and Process for Making Them
WO2009024889A2 (en) *	2007-08-21	2009-02-26	Ranbaxy Laboratories Limited	Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CA2725680A1 (en)	2008-05-30	2009-12-03	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP2011525901A (ja)	2008-06-27	2011-09-29	アブディイブラヒムイラクサナイベティカレットアノニムシルケティ	ロスバスタチンカルシウム含有医薬組成物
ES2382773T3 (es)	2009-03-13	2012-06-13	Sanovel Ilac Sanayi Ve Ticaret A.S.	Composiciones de ezetimiba
US20110196383A1 (en)	2009-05-05	2011-08-11	Atherolysis Medical, Inc	Atherosclerotic Plaque Dissolution Composition
WO2011019326A2 (en)	2009-07-02	2011-02-17	Mahmut Bilgic	Solubility and stability enchancing pharmaceutical formulation
EP2566465A2 (en)	2010-05-04	2013-03-13	Mahmut Bilgic	Stable rosuvastatin formulations
TR201009397A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Rosuvastatin içeren farmasötik bileşimler.
KR101248804B1 (ko) *	2010-05-14	2013-03-29	한미사이언스 주식회사	ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2468258A1 (en) *	2010-12-22	2012-06-27	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) *	2011-10-13	2013-05-10	Mahmut Bilgic	Solid dosage forms comprising ezetimibe
DK2844233T3 (da) *	2012-05-01	2020-07-13	Althera Life Sciences Llc	Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
WO2013176455A1 (ko) *	2012-05-22	2013-11-28	건일제약 주식회사	오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
MX2012014970A (es) *	2012-12-18	2013-08-27	Hetlabs Mexico S A De C V	Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
KR102240429B1 (ko) *	2013-05-06	2021-04-15	한미약품 주식회사	로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

2014
- 2014-06-11 KR KR1020140071081A patent/KR20150079373A/ko unknown
- 2014-12-29 KR KR1020140192374A patent/KR20150079454A/ko active Search and Examination
- 2014-12-29 UY UY0001035932A patent/UY35932A/es not_active Application Discontinuation
- 2014-12-29 TW TW103146067A patent/TWI655944B/zh not_active IP Right Cessation
- 2014-12-30 AR ARP140104955A patent/AR098996A1/es unknown
- 2014-12-30 PE PE2016000976A patent/PE20161072A1/es unknown
- 2014-12-30 US US15/108,940 patent/US10434067B2/en not_active Expired - Fee Related
- 2014-12-30 SG SG10201805657PA patent/SG10201805657PA/en unknown
- 2014-12-30 WO PCT/KR2014/013087 patent/WO2015102400A1/en active Application Filing
- 2014-12-30 CR CR20160293A patent/CR20160293A/es unknown
- 2014-12-30 JP JP2016537529A patent/JP2017500303A/ja active Pending
- 2014-12-30 AU AU2014374552A patent/AU2014374552B2/en not_active Expired - Fee Related
- 2014-12-30 UA UAA201605792A patent/UA117685C2/uk unknown
- 2014-12-30 CA CA2933178A patent/CA2933178A1/en not_active Abandoned
- 2014-12-30 EP EP14876988.8A patent/EP3089739A4/en not_active Withdrawn
- 2014-12-30 RU RU2016123828A patent/RU2683937C2/ru active
- 2014-12-30 CN CN201480071651.8A patent/CN105873571B/zh active Active
- 2014-12-30 MX MX2016008725A patent/MX2016008725A/es unknown
- 2014-12-30 MY MYPI2016000980A patent/MY187637A/en unknown
2016
- 2016-06-09 ZA ZA2016/03934A patent/ZA201603934B/en unknown
- 2016-06-17 PH PH12016501196A patent/PH12016501196B1/en unknown
- 2016-06-24 DO DO2016000159A patent/DOP2016000159A/es unknown
- 2016-06-28 NI NI201600093A patent/NI201600093A/es unknown
- 2016-06-28 SV SV2016005236A patent/SV2016005236A/es unknown
- 2016-06-28 CL CL2016001654A patent/CL2016001654A1/es unknown
- 2016-06-28 GT GT201600137A patent/GT201600137A/es unknown

Also Published As

Publication number	Publication date
RU2683937C2 (ru)	2019-04-03
CR20160293A (es)	2016-10-05
MY187637A (en)	2021-10-05
CN105873571A (zh)	2016-08-17
TW201609091A (zh)	2016-03-16
UA117685C2 (uk)	2018-09-10
PH12016501196A1 (en)	2016-08-15
RU2016123828A3 (es)	2018-08-28
DOP2016000159A (es)	2016-12-15
CA2933178A1 (en)	2015-07-09
AR098996A1 (es)	2016-06-22
PE20161072A1 (es)	2016-11-04
EP3089739A4 (en)	2017-08-02
NI201600093A (es)	2016-07-22
EP3089739A1 (en)	2016-11-09
UY35932A (es)	2015-07-31
AU2014374552B2 (en)	2019-09-19
WO2015102400A1 (en)	2015-07-09
US20160346213A1 (en)	2016-12-01
KR20150079373A (ko)	2015-07-08
SV2016005236A (es)	2016-11-03
US10434067B2 (en)	2019-10-08
JP2017500303A (ja)	2017-01-05
KR20150079454A (ko)	2015-07-08
ZA201603934B (en)	2017-09-27
MX2016008725A (es)	2017-02-28
TWI655944B (zh)	2019-04-11
GT201600137A (es)	2018-10-19
AU2014374552A1 (en)	2016-06-02
PH12016501196B1 (en)	2016-08-15
CN105873571B (zh)	2019-10-22
RU2016123828A (ru)	2018-02-07
CL2016001654A1 (es)	2017-01-06

Publication	Publication Date	Title
SG10201805657PA (en)	2018-08-30	Composite formulation for oral administration comprising ezetimibe and rosuvastatin
SG10201811586YA (en)	2019-02-27	Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
WO2014114255A3 (zh)	2014-09-25	一种定位速释生物粘附剂及应用
ZA201500920B (en)	2017-01-25	3-substituted estra-1,3,5(10),16-tetraene derivatives ,methods for the production thereof ,pharmaceutical preparations contaning same,and use thereof for the production of medicaments
PH12017502376B1 (en)	2018-06-25	Oral solid formulation containing irinotecan and method of preparing the same
HUE040666T2 (hu)	2019-08-28	Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció
WO2017103600A8 (en)	2018-07-12	Preparation of respirable zafirlukast particles
MD4563B1 (ro)	2018-05-31	Produs de comicronizare cu conţinut de acetat de ulipristal
MX2014013664A (es)	2015-04-17	N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
PH12015500395A1 (en)	2015-04-27	Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
AU2014226192A8 (en)	2016-04-21	Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2014167579A3 (en)	2014-12-24	Stable pharmaceutical compositions of tadalafil
PL408608A1 (pl)	2015-12-21	Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
MX368640B (es)	2019-10-09	Composición farmacéutica para tratar inflamación y dolor.
EP3797446A4 (en)	2022-03-16	METHODS FOR PREPARING PARTICLE PRECURSOR AND CATHODE ACTIVE PARTICLES, AND PARTICLE PRECURSOR SO PREPARED
WO2014062568A3 (en)	2014-11-20	Amoxicillin formulation and method of using such formulation
WO2013111013A3 (en)	2013-10-31	Methods for treating alzheimer's disease by administering certain synthetic compounds
WO2016126115A3 (en)	2016-10-06	Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
EP3648745A4 (en)	2021-05-12	PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION
EP3673901A4 (en)	2021-05-19	PARTICLES OF A PHARMACEUTICAL COMPOSITION, ORAL DISCLOSURE PREPARATION THEREOF AND PROCESS FOR THE PREPARATION OF PARTICLES OF A PHARMACEUTICAL COMPOSITION
NZ728386A (en)	2018-02-23	Use of phthalide compound
PH12015502435A1 (en)	2016-02-22	Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole